array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(65) "Advanced melanoma: BioNTech mRNA vaccine and cemiplimab effective" ["snippet_en"]=> string(123) "Advanced melanoma: BioNTech's mRNA vaccine plus cemiplimab boosts responses in patients already treated with immunotherapy." ["url"]=> string(111) "https://www.corrierenazionale.it/2024/09/16/melanoma-avanzato-vaccino-a-mrna-di-biontech-e-cemiplimab-efficaci/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/275bb211-544e-4faa-a4ed-092b59d47926" ["source"]=> string(20) "corrierenazionale.it" ["publication_date"]=> string(10) "2024-09-16" ["categories"]=> array(2) { [0]=> string(24) "Access and affordability" [1]=> string(17) "Academic Research" } } [1]=> array(7) { ["title_en"]=> string(59) "Regeneron joins Koneksa Parkinson's digital biomarker study" ["snippet_en"]=> string(131) "Regeneron signs up for access to a study run by Koneksa exploring the use of digital biomarkers to track patients with Parkinson's." ["url"]=> string(88) "https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study" ["image_url"]=> string(78) "https://images.businessradar.com/articles/77d41efd-0dce-41ee-91b7-359165fc4f98" ["source"]=> string(16) "pharmaphorum.com" ["publication_date"]=> string(10) "2024-09-04" ["categories"]=> array(5) { [0]=> string(16) "Customer Privacy" [1]=> string(10) "Cybercrime" [2]=> string(17) "Academic Research" [3]=> string(13) "Data Security" [4]=> string(24) "Access and affordability" } } [2]=> array(7) { ["title_en"]=> string(112) "Our drug pricing system is broken. A Prescription Drug Affordability Board could help fix it. - Virginia Mercury" ["snippet_en"]=> string(158) "Setting limits on high-cost drugs is the right thing to do, especially in Virginia, whose residents spend more money on our prescriptions than most Americans." ["url"]=> string(131) "https://virginiamercury.com/2024/02/29/our-drug-pricing-system-is-broken-a-prescription-drug-affordability-board-could-help-fix-it/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/11daa347-d023-457a-bc46-6c3fc444e90d" ["source"]=> string(19) "virginiamercury.com" ["publication_date"]=> string(10) "2024-02-29" ["categories"]=> array(2) { [0]=> string(24) "Access and affordability" [1]=> string(21) "Shareholders Feedback" } } [3]=> array(7) { ["title_en"]=> string(62) "Guest opinion: A New Year’s resolution – Lower drug prices" ["snippet_en"]=> string(237) "Each January, many Utahns and other Americans resolve to take steps to improve their health over the coming year. Why not also ask Congress to make a resolution that can help us all: voting to reform our prescription drug pricing system?" ["url"]=> string(129) "https://www.heraldextra.com/news/opinion/local-guest-opinions/2024/jan/30/guest-opinion-a-new-years-resolution-lower-drug-prices/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/2cbefa9b-dcf3-4cfd-9488-2c94e022b000" ["source"]=> string(15) "heraldextra.com" ["publication_date"]=> string(10) "2024-01-29" ["categories"]=> array(2) { [0]=> string(24) "Access and affordability" [1]=> string(21) "Intellectual Property" } } [4]=> array(7) { ["title_en"]=> string(32) "Health Care Roundup: Market Talk" ["snippet_en"]=> string(134) "Find insight on Helen of Troy, Sanofi, Regeneron Pharmaceuticals and more in the latest Market Talks covering the Health Care sector." ["url"]=> string(74) "https://www.wsj.com/health/pharma/health-care-roundup-market-talk-9be34cf2" ["image_url"]=> string(78) "https://images.businessradar.com/articles/677d9872-b550-40fd-8cd7-8862120f1ed8" ["source"]=> string(7) "wsj.com" ["publication_date"]=> string(10) "2024-01-08" ["categories"]=> array(5) { [0]=> string(11) "Competition" [1]=> string(15) "Market Movement" [2]=> string(24) "Employee Health & Safety" [3]=> string(16) "Customer Welfare" [4]=> string(24) "Access and affordability" } } [5]=> array(7) { ["title_en"]=> string(128) "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries" ["snippet_en"]=> string(158) "/PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international..." ["url"]=> string(182) "https://www.prnewswire.co.uk/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a5536b51-142d-4a07-8c9b-f46a94f9b2c2" ["source"]=> string(16) "prnewswire.co.uk" ["publication_date"]=> string(10) "2024-01-08" ["categories"]=> array(3) { [0]=> string(24) "Access and affordability" [1]=> string(15) "Deals & Tenders" [2]=> string(13) "Collaboration" } } [6]=> array(7) { ["title_en"]=> string(73) "Top 10 Hearing News Stories of 2023 | Hearing Health & Technology Matters" ["snippet_en"]=> string(96) "In 2023, the landscape of hearing healthcare experienced remarkable activity and pivotal shifts." ["url"]=> string(79) "https://hearinghealthmatters.org/hearing-news-watch/2023/top-10-audiology-news/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/72fe557d-deae-43f0-abbd-41cb1875b171" ["source"]=> string(24) "hearinghealthmatters.org" ["publication_date"]=> string(10) "2023-12-23" ["categories"]=> array(1) { [0]=> string(24) "Access and affordability" } } [7]=> array(7) { ["title_en"]=> string(102) "White House keeps focus on lowering drug prices, turns Regeneron's contract language into new standard" ["snippet_en"]=> string(285) "As President Joe Biden struggles in the most recent 2024 general election polls, the White House is keeping its focus on drug prices, going after pharma for the second time in as many weeks, with plans to find new ways to interact with industry on the federal government's terms. While" ["url"]=> string(120) "https://endpts.com/white-house-keeps-focus-on-lowering-drug-prices-turns-regenerons-contract-language-into-new-standard/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a8dc7049-0cf9-4523-8a5e-cc5c3d0ba73d" ["source"]=> string(10) "endpts.com" ["publication_date"]=> string(10) "2023-12-14" ["categories"]=> array(6) { [0]=> string(19) "Government Policies" [1]=> string(8) "Politics" [2]=> string(24) "Government Interventions" [3]=> string(20) "Contract negotiation" [4]=> string(11) "US Politics" [5]=> string(24) "Access and affordability" } } [8]=> array(7) { ["title_en"]=> string(18) "ADVENT Dermatology" ["snippet_en"]=> string(119) "ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron..." ["url"]=> string(79) "https://www.emjreviews.com/dermatology/infographics/advent-dermatology-j030123/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/8ca73ff1-f102-461d-97ee-30543d4febf7" ["source"]=> string(14) "emjreviews.com" ["publication_date"]=> string(10) "2023-11-23" ["categories"]=> array(1) { [0]=> string(24) "Access and affordability" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc